Going Solo Suits Vifor And Its Hopes For Two Blockbusters
Enjoying its independence from Galenica, Switzerland’s third-largest pharmaceutical company believes that Ferinject and Veltassa will help it achieve sales of over CHF2bn by 2020.
You may also be interested in...
AstraZeneca’s Lokelma and Vifor’s Veltassa will be subject to a final review by the England and Wales health technology appraisal body in December following draft guidance not recommending their use in the National Health Service to treat hyperkalemia.
The treatment of hyperkalemia in Europe in patients with chronic kidney disease or chronic heart failure looks set to become more vibrant, with AstraZeneca's Lokelma likely to join Vifor Pharma's Veltassa in the marketplace.
With a new hyperkalemia therapy nearing EU markets and its injectable iron product showing strong sales growth, Switzerland’s global specialty pharma company Vifor Pharma has been able to upgrade its financial guidance for 2017.